This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy. The NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years. This study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine / Allergology
Study Type
OBSERVATIONAL
Enrollment
200
AIT for airborn allergens (SCIT/SLIT)
NAPT test with airborn allergens ( HDM, Threes, Grasses)
UZ Leuven
Leuven, Vlaam Brabant, Belgium
RECRUITINGAZ Sint-Jan
Bruges, Belgium
NOT_YET_RECRUITINGThe effectiveness of AIT treatment assessed by the change in the blood concentration in total en specific IgE .
The effectiveness of AIT treatment will be analysed by comparing blood results, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up).
Time frame: before start AIT, every 6 months en after 3 years
The effectiveness of AIT treatment assessed by the change in quality of life meassured by the Lebelscore.
The effectiveness of AIT treatment will be analysed by comparing the Lebelscores ,assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). Lebelscore has a range between 0 and 12.
Time frame: Before start AIT, every 6 months en after 3 years
The effectiveness of AIT treatment assessed by the change in quality of life meassured by the SNOT-22.
The effectiveness of AIT treatment will be analysed by comparing SNOT-22, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). SNOT-22 is sino-nasal outcome test with 22 items which ranges from 0 to 110.
Time frame: Before start AIT, every 6 months en after 3 years
The effectiveness of AIT treatment assessed by the change in quality of life meassured by the VAS.
The effectiveness of AIT treatment will be analysed by comparing VAS, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). The visual analogue scale (VAS) ranges from 0 to 10cm for every item.
Time frame: Before start AIT, every 6 months en after 3 years
The effectiveness of AIT treatment assessed by the change in quality of life meassured by the TNSS.
The effectiveness of AIT treatment will be analysed by comparing TNSS, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). Total nasal symptom score (TNSS) ranges from 0 to 12.
Time frame: Before start AIT, every 6 months en after 3 years
The effectiveness of AIT treatment assessed by the change in quality of life meassured by the ACT.
The effectiveness of AIT treatment will be analysed by comparing ACT, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). ACT is the Asthma control test with scores between 0 and 25. The higher the score the better.
Time frame: Before start AIT, every 6 months en after 3 years
The effectiveness of AIT treatment assessed by the change in quality of life meassured by the RQLQ.
The effectiveness of AIT treatment will be analysed by comparing RQLQ, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). RQLQ is the rhinoconjunctivits quality of life questionnaire with scores between 0 and 168. The higher the score of these questionnaires the more discomfort.
Time frame: Before start AIT, every 6 months en after 3 years
The effectiveness of AIT treatment assessed by the change in quality of life meassured by the TRE.
The effectiveness of AIT treatment will be analysed by comparing TRE, assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). TRE is the therapeutic response evaluation and will be scored between 'much better' and 'much worse'.
Time frame: Before start AIT, every 6 months en after 3 years
The effectiveness of AIT treatment assessed by the change in the PNIF value.
The effectiveness of AIT treatment will be analysed by comparing PNIF values assessed by the NAPT tests, before, during (every 6 months after starting AIT) and after end of treatment (approximately 3 years after start-up). PNIF is the peak nasal inspiratory flow with a value between 0 and 370 l/min). The higher the value the less congested the nose is.
Time frame: Before start AIT, every 6 months en after 3 years
Calculating the cost savings by desensitizing poly-sensitized patients only to the allergen to which they respond most strongly in the NAPT test.
Time frame: 3 years
Calculating the cost savings by timely stopping AIT treatment in non-responders, which we can define as patients who do not experience subjective or objective improvement after 1 year of treatment.
Time frame: 3 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.